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Abstract 
The prevalence of chloroquine-resistant Plasmodium falciparum malaria has been increasing in sub- 
Saharan Africa and parts of South America over the last 2 decades, and has been associated with 
increased anaemia-associated morbidity and higher mortality rates. Prospectively collected clinical and 
parasitological data from a multicentre study of 788 children aged 6-59 months with uncomplicated 
P. falciparum malaria were analysed in order to identify risk factors for chloroquine treatment failure and 
to assess its impact on anaemia fter therapy. The proportion of chloroquine treatment failures (com- 
bined early and late treatment failures) was higher in the central-eastern African countries (Tanzania, 
53%; Uganda, 80%; Zambia, 57%) and Ecuador (54%) than in Ghana (36%). Using logistic regression, 
predictors of early treatment failure included younger age, higher baseline temperature, and greater levels 
of parasitaemia. We conclude that younger age, higher initial temperature, and higher baseline 
parasitaemia predict early treatment failure and a higher probability of worsening anaemia between 
admission and days 7 or 14 post-treatment. 
Keywords: malaria, Plasmodium falciparum, anaemia, chloroquine, treatment failure, Africa, Ecuador 
Introduction 
Plasmodium falciparum malaria is a major cause of 
morbidity and mortality worldwide, especially in sub- 
Saharan Africa. Levels of chloroquine resistance have 
steadily increased over the last 2 decades in Africa 
(F~han & Macguire, 1978; Brandling-Bennett et al., 
1988; Watkins et al., 1988; Premji et al., 1994; Bloland 
et al., 1998; Makono & Sibanda, 1999) and in some 
areas of South America (Blair-Trujillo et al., 2002; 
Marquifio et al., 2003). The continued use of chloro- 
quine as first-line therapy for malaria increases the risk 
of anaemia and the need for blood transfusions in 
young children (Greenberg er al., 1989; Ekvall et al., 
1998; McElroy et al., 2000). In Africa, chloroquine 
resistance has been associated with increased mortality, 
particularly in children aged < 5 years (Zucker et al., 
1996; Trape et al., 1998). 
Effective treatment of malaria reduces the risk of 
death in children with severe anaemia (Zucker et al., 
1996). In a community-based study of Tanzanian chil- 
dren, early treatment failure (ETF) with chloroquine 
was associated with a greater decrease in haemoglobin 
(Hb) level after 72 h than late treatment failure (LTF) 
or adequate clinical response (ACR). Despite ACR to 
chloroquine, no improvement in Hb levels was seen 
during follow-up greater than 21 d after initial therapy. 
In contrast, treatment with sulfadoxine-pyrimetha- 
mine (SP) resulted in significant improvement in Hb 
levels (EkvaU et al., 1998). 
Despite rising levels of resistance, chloroquine con- 
tinues to be the antimalarial treatment of choice in 
many countries, because it is well tolerated, safe, in- 
expensive, and highly effective against susceptible 
strains of P. falciparum. Treatment with chloroquine 
often leads to rapid symptomatic improvement in 
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patients with malaria despite failure of the drug to 
clear parasites from the blood (Hoffman et al., 1984; 
Khoromana et al., 1986; Brandling-Bennett e  al., 
1988). Given the lack of inexpensive, non-toxic, and 
effective alternatives, the continued use of chloroquine 
in countries or regions with lower levels of resistance 
seems to be a reasonable approach until a better alter- 
native becomes available and affordable. 
In a study of children with uncomplicated P. falci- 
parum malaria, conducted in the Solomon Islands, 
independent risk factors for chloroquine resistance in- 
cluded young age, high parasite density, normal spleen 
size, malnutrition, and the presence of gametocytes in
thick films (Hess et el., 1996). Using multivariate analy- 
sis, a recent study in Uganda found that age < 5 years, 
presenting temperature > 38.0 °C, and chloroquine use 
3-4 d before study entry were independent predictors 
of chloroquine treatment failure (Dorsey et al., 2000). 
While other studies have attempted to define risk fac- 
tors for chloroquine treatment failure, methodological 
differences, small sample size, and failure to control 
for potentially confounding effects serve to limit the 
strength of their results (Brandling-Bennett t el., 1988; 
Henry et al., 1994, 1996; Alene & Bennett, 1996; 
Ekvall et al., 1998). In addition, most studies have 
focused on only 1 country. 
During the course of a randomized, placebo- 
controlled, multicentre trial of zinc as an adjunct o the 
treatment of acute, uncomplicated P. falciparum malar- 
ia in young children, data were prospectively collected 
on ETF and LTF with chloroquine (ZAP, 2002). This 
paper characterizes and contrasts chloroquine resis- 
tance in vivo in the 5 participating study sites and 
attempts to identify independent risk factors for chloro- 
quine treatment failure and persistent anaemia fter an 
episode of malaria.. 
Methods 
Full details concerning the study design and methods 
can be found elsewhere (ZAP, 2002). In order 
to ensure uniformity of data collection across study 
sites, we used a common protocol, a detailed study 
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procedure manual, pilot studies at each site, and tech- 
nical site visits at the beginning of enrolment in order 
to assess and ensure uniformity of study procedures. 
Special quality control measures were used to ensure 
consistency in the performance and interpretation of
blood films among the study sites. Internal quality 
control consisted of duplicate reading of a 10% sub- 
sample of smears by an experienced parasitologist at 
each site. while external quality control was done on a 
5% sample of slides from all sites by an experienced 
parasitologist (Z. G. P.). 
Study sites 
Subject enrolment took place between December 
1998 and May 2000 at the following locations: Hospital 
Delfina Torres (Esmeraldas, Ecuador), Komfo Anokye 
Teaching Hospital (Kumasi, Ghana), Kisarawe District 
Hospital (Kisarawe, Tanzania), Mpigi Health Center 
(Mpigi, Uganda), and Arthur Davison Children Hospi- 
tal (Ndola, Zambia). These sites represent a mixture 
of urban and rural populations in Africa and Latin 
America. The 4 African sites are in malaria hyper- 
holoendemic zones whereas the Ecuadorian site is in a 
hypoendemic zone. 
Study subjects 
Children aged 6-59 months with axillary tempera- 
ture i> 37.5°C and i> 2000/mm 3 asexual forms of 
P. falciparum in a thick blood film were eligible for 
participation i the study. Exclusion criteria included: 
Hb < 70 g/L, severe malaria as defined by WHO 
(1990), non-P, falciparum or mixed Plasmodium infec- 
tions, concurrent severe infections (i.e. lower respi- 
ratory infection, acute otitis media, pyelonephritis, 
typhoid fever, bloody diarrhoea, meningitis, or 
measles), severe dehydration, malnutrition as defined 
by the Wellcome criteria (Anonymous, 1970), inability 
to tolerate oral medications or fluids, chronic illness, 
and prior participation i  the trial. Written informed 
consent was obtained from the child's parent or carer. 
The institutional review boards at each site and the 
Harvard School of Public Health, Boston, MA, USA, 
approved the study. 
Once enrolled, children were admitted to an in- 
patient ward for 48-72 h. Demographic data, use of 
antivector measures to prevent malaria, recent anti- 
malarial use, and significant past medical history were 
collected. A complete physical examination was per- 
formed at the time of study entry and daily during 
hospitalization a d as clinically indicated. Axillary tem- 
perature was measured every 4 h. Paracetamol was 
administered for temperatures i> 38.5 °C every 6 h at a 
dose of 10-15 mg/kg. 
Antimalarial treatment and follow-up 
Chloroquine was the recommended first-line drug 
for the treatment of malaria in all 5 countries during 
the study period. The following dosing schedule was 
used: 10 mg/kg on day 0, 10 mg/kg on day 1, and 
5 mg/kg on day 2. If either a treatment or parasitologi- 
cal failure occurred (see outcome classifications for 
definitions), treatment with a standard ose of either 
amodiaquine or SP (Fansidar, Roche, Zurich, Switzer- 
land) was administered. Quinine was used for the 
treatment of children who developed severe malaria 
(WHO, 1990). Children with symptomatic severe 
anaemia were transfused with packed red blood cells. 
Discharge from hospital occurred once the fever had 
resolved (axillary temperature < 37.5 °C for at least 12 
h) and there was a /> 75% reduction of parasitaemia 
relative to baseline. 
Children were seen at follow-up at the health centre 
on days 7, 14, and 28. If the patient did not return for 
follow-up, a research assistant went to the subject's 
house to locate the patient. At each follow-up visit, a 
history of fever during the last week and recent anti- 
malarial drug use were collected, blood smears were 
performed, and Hb was measured. 
Laboratory tests 
Giemsa-stained thick blood films were prepared at 
the time of enrolment, at 24 h, 36 h, 48 h, 72 h, and at 
days 7, 14, and 28. Total parasite count per microlitre 
was quantitated by counting the number of parasites 
per 200 white blood cells (WBC), assuming a total 
WBC count of 8000/pL (Trape, 1985). A thick film 
was declared negative after viewing high power fields 
containing 500 WBCs. The Hb concentration was 
determined by HemoCue (Angelholm, Sweden) on 
admission and on days 7, 14, and 28. 
Outcome classification 
Therapeutic response was defined using a modified 
version of the WHO 14-day in vivo clinical classifica- 
tion system (WHO, 1996; Table 1). The definition of 
LTF was modified as follows. Because axillary tem- 
peratures were not taken during follow-up home visits, 
we used a history of fever during the last week instead 
of axillary temperature and history of fever in the 
previous 48 h. We also used a history of hospitalization 
with parasitaemia in place of severe malaria/danger 
signs with parasitaemia. The response to chloroquine 
treatment was also classified according to the WHO 
parasitological classification system (WHO, 1973; 
Table 1). 
Data management and statistical methods 
Data entry and management was carried out using 
Epi-Info, version 6.04c (CDC, Atlanta, GA, USA) and 
Integrated Microcomputer Processing System, version 
3.1 (US Bureau of Census, Washington, D.C., USA). 
Since there was no effect of the zinc supplement on 
clinical, parasitological, or haematological outcomes 
(ZAP, 2002), the 2 treatment groups were combined 
for the purposes of this analysis. 
Statistical analyses were carried out using SAS, ver- 
sion 8.2 (SAS Institute Inc., Cary, NC, USA). Odds 
ratios and 95% CIs were predicted from logistic regres- 
sion parameter estimates and Wald confidence inter- 
vals. Multiple logistic regression models for predictors 
of ACR, ETF, and LTF created models that initially 
included study site, age in months, use of bednets, 
initial temperature, log-transformed baseline parasitae- 
mia, baseline Hb, gender, use of personal antimosquito 
control, use of antimalarials in the previous 7 d, breast- 
feeding, mother literate, weight-for-age Z-score, 
height-for-age Z-score, and whether the subject was 
randomized toreceive zinc. 
Predicators of Hb change were modelled with multi- 
variate, repeated measures analysis of variance 
(ANOVA). The model initially included an indicator 
variable for ACR, study site, age in months, use of 
bednets, initial temperature, log-transformed baseline 
parasitaemia, gender, use of personal antimosquito 
control, use of antimalarials in the previous 7 d, breast- 
feeding, mother literate, weight-for-age Z-score, 
height-for-age Z-score, and whether the subject was 
randomized toreceive zinc. 
Both final models were constructed using a back- 
wards elimination selection process and these models 
were confirmed with a forward selection process. All 
models included indicator variables for study site. 
Two-way interactions of statistically significant main 
effects were tested. 
Results 
Baseline characteristics 
One thousand and eighty-seven children were en- 
rolled. The analytical data set consisted of the 788 
children for whom complete clinical and parasitological 
data were available. Baseline characteristics of the study 
participants, broken down by site of enrolment, are 
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Table 1. Definitions of clinical and parasitological outcomes in study children with uncomplicated 
Plasmodium falciparum malaria 
Definition 
Clinical outcome 
Early treatment failure (ETF) 
Late treatment failure (LTF) 
Adequate clinical response (ACR) 
Parasitological outcome 
Sensitivity (S) 
RI 
RII 
RIII 
Any of the following occurring on days 1-3: 
1. Development ofsevere malaria/danger signs (unconsciousness, 
prostration, convulsions, persistent vomiting, severe anaemia) with 
parasitaemia 
2. Axillary temperature ~> 37.5 °C on day 2 with parasite density > day 0 
parasite density 
3. Axillary temperature i> 37.5 °C on day 3 with parasitaemia 
4. Day 3 parasite density > 25% day 0 parasite density 
Any of the following occurring on days 4-14: 
1. Hospitalization with parasitaemia 
2. Report of fever since last visit with parasitaemia 
1. Absence ofparasitaemia onday 14 irrespective ofaxillary temperature 
without meeting any of the criteria of ETF or LTF 
2. No report of fever irrespective ofthe presence of parasitaemia, without 
meeting any of the criteria of ETF or LTF 
Asexual parasitaemia is reduced to 25 % or less of the original pre-test level 
during the first 48 h of treatment. Asexual parasitaemia clears by day 7 and 
does not reappear 
Asexual parasitaemia is reduced to 25% or less of the original pre-test level 
during the first 48 h of treatment. Asexual parasitaemia clears by day 7, but 
reappears on either day 14 or day 28 
Asexual parasitaemia is reduced to 25 % or less of the original pre-test level 
during the first 48 h of treatment. Asexual parasitaemia never clears 
Asexual parasitaemia is reduced by less than 75% during the first 48 h or it 
continues to rise 
displayed in Table 2. We compared the baseline demo- 
graphic, clinical, and parasitological characteristics of
the group of children who were excluded from analysis 
with the group for whom we had complete data, and 
found few differences. There was greater bednet use in 
the group with complete data. Subjects in Ecuador 
tended to be older (mean age 39.2 months) than those 
in the African sites (mean age 25.4 months) and had 
significantly lower geometric mean parasite counts 
(9450 vs. 19 930/pL). Lastly, children in Uganda had a 
lower mean height-for-age Z-score. 
The children enrolled from Tanzania and Zambia 
had higher levels of parasitaemia than those from Gha- 
na, Uganda, or Ecuador. Baseline Hb levels and bednet 
use varied widely across sites. The reported use of 
antimalarials in the week before hospitalization varied 
from 17% in Ecuador to 54% in Uganda. Chloroquine 
was by far the most commonly used antimalarial overall 
(92% overall). 
Clinical and parasitological outcomes 
Chloroquine treatment failures were common in 
Central-East Africa and Ecuador with ETFs ranging 
from 38 to 65%. Significantly more children in Ghana 
had ACRs than children in the other 4 countries com- 
bined (P< 0.0001). Parasitological resistance results 
are displayed in Table 3. Combined RII and RIII 
resistance was > 50% in all countries except Ghana 
(48.7%). A moderate number of discordant results 
were encountered when parasitological resistance rates 
were compared with ETF and LTF (Table 4). We 
combined S and RI (which are closest o the definition 
of ACR) and computed a ~c statistic to compare the 
concordance between the 2 classification systems. The 
agreement between the 2 systems was 67% and had a K 
coefficient of 0.48 (P < 0.0001). 
ETF occurred in 17.1% (48/280) of children with 
RI or S parasitological outcomes. Although there ap- 
peared to be discordance between the presence of RIII 
parasitological resistance and an ACR in 52 children, 
this discrepancy proved to be a result of how RIII was 
defined. All 52 children failed to have a reduction to 
25% of baseline parasitaemia by 48 h (therefore meet- 
ing the definition of RIII) but, by 72 h, parasitaemia 
had dropped below 25% (thus not fulfilling the criteria 
for ETF). Surprisingly, 20.2% (68/337) of children 
with ACRs had RII resistance. 
Predictors of treatment failure 
Logistic regression analysis was used to identify pos- 
sible predictors of chloroquine treatment failure (com- 
bined ETF and LTF). Univariate predictors of ETF 
included younger age, increased temperature at base- 
line, higher parasitaemia at presentation, and current 
breastfeeding. Gender, zinc treatment, bednet use, use 
of antivector measures, height-for-age Z-score, weight- 
for-age Z-score, baseline zinc plasma levels, and history 
of recent antimalarial therapy were not significantly 
associated with treatment failure. The risk of chloro- 
quine treatment failure increased with decreasing age, 
higher baseline temperature, and greater density of 
baseline parasitaemia (Table 5). In the presence of the 
variable age, breastfeeding was not a predictor of treat- 
ment failure. A full model was fitted, controlling for 
study site, gender, zinc treatment, bednet use, use of 
antivector measures, height-for-age Z-score, weight- 
for-age Z-score, baseline zinc plasma levels, and history 
of recent antimalarial therapy. However, the inclusion 
of the additional terms had only minor impact on the 
odds ratios and 95% CIs. 
Haematological outcomes 
Most subjects (84%) were anaemic (Hb < 110 g/L) 
at baseline. In the overall study cohort, Hb levels 
declined between days 0 and day 7 from a mean of 
92.6 g/L to 87.2 g/L. Subsequently, the Hb concentra- 
tion began to rise, reaching a mean of 95.5 g/L at day 
14 and 100.9 g/L at day 28. The final value at day 28 
was a mean of 8.3 g/L, higher than at the time of 
presentation to the hospital. Children who had an ACR 
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to chloroquine had significantly higher Hb concentra- 
tions at days 7 (P< 0.0001) and 14 (P= 0.0057) when 
compared with those with ETF or those with combined 
ETF and LTF (Figure). The day 28 Hb level was 
higher in children who had an ACR but the difference 
was not statistically significant (P = 0.84). 
Predictors of differences in haemoglobin from day 0 to 28 
Risk factors for differences in Hb between the initia- 
tion of therapy and day 28 were identified using a 
repeated measures ANOVA. Predictors of differences 
in Hb included age (P < 0.0001), initial parasitaemia 
(P= 0.0004), and recent antimalarial therapy (P= 
0.0073) controlling for initial temperature, study site, 
gender, zinc treatment, bednet use, other antivector 
measure use, and ACR. 
Discuss ion 
Our study demonstrated high rates of chloroquine 
treatment failure in Ecuador, Tanzania, Uganda, and 
Zambia and moderate levels of resistance in Ghana. 
Only 20% of children in Uganda and less than half the 
children in Ecuador, Tanzania, and Zambia had an 
ACR to chloroquine. Although Ghanaian children had 
better clinical responses (64.1%), the treatment failure 
rate was nonetheless above the 25% threshold recom- 
mended by the WHO for a change in national drug 
policy (WHO 1996). 
The rate of resistance ncountered in Uganda was 
higher than recently described. Dorsey et al. (2000) 
found a treatment failure rate of 47% compared with 
80% in our study. One possible xplanation is that the 
Dorsey study included adults who are more likely to 
have underlying antimalarial immunity. The ability to 
clear chloroquine-resistant parasites after treatment im- 
proves with age (Djimb6 et al., 2001). 
The chloroquine resistance rates in Tanzania were 
similar to those that have been previously reported 
(Premji et al., 1994; Ekvall et al., 2001). Similarly, high 
rates of chloroquine treatment failures have also been 
described in Zambia (Barat et al., 1998). At the time 
that we carried out this study, the Ministries of Health 
of all of the 5 participating countries were still recom- 
mending the use of chloroquine as a first-line agent for 
the treatment of uncomplicated malaria in children. 
The results of our study provide further data to uphold 
the decisions that have subsequently been made by the 
Ministries of Health in Tanzania, Uganda, and Zambia 
to change from chloroquine as first-line therapy (Moll, 
Tanzania, 1999; Moll ,  Uganda, 2001; Moll ,  Zambia, 
2002). In Tanzania, although the Ministry of Health 
officially recommended discontinuing the use of chlor- 
oquine as the first-line drug, there continues to be 
extensive use of chloroquine in non-governmental 
health facilities and private practice associated with 
practitioner and community concerns about SP safety 
and cost. Similarly, in Zambia, although an official 
recommendation to change malaria drug policy has 
been made, the process of conversion to SP as an 
intermediate strategy prior to the introduction of arte- 
sunate-based combination therapy is proving to be 
logistically complicated. Thus, the findings of our study 
remain relevant to these countries. 
The ~ coefficient of 48% represents a moderate 
agreement above chance between the 2 classification 
systems, indicating that we found a moderate level of 
discordance between the presence of parasitological 
resistance and clinical outcomes, especially when resis- 
tance was compared with ACRs. Some of this discre- 
pancy might have stemmed from our relatively strict 
adherence to standard WHO definitions (WHO, 1973, 
1996). Many children had evidence of RI or RII resis- 
tance but nevertheless had ACRs. Similar findings were 
noted in a study of chloroquine resistance in Mali in 
which children aged < 5 years were more likely than 
older persons to have discordance between ACR and 
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Table 3. Parasitological outcomes in study children with uncomplicated 
P lasmod ium fa lc iparum malaria 
Study site No. RIII (%) RII (%) RI (%) S (%) 
Ecuador 71 38.0 36.6 19.7 5.6 
Ghana 131 22.1 26.7 20.6 30.5 
Tanzania 182 36.3 20.3 23.6 19.8 
Uganda 180 62.8 28.3 7.2 1.7 
Zambia 224 39.3 16.1 24.1 20.5 
All Sites 788 40.9 23.5 19.2 16.4 
Table 4. Comparison of clinical and parasitological outcomes in study 
children with uncomplicated P lasmod iumfa lc iparum malar ia  for all study 
sites 
Outcome RIII RII RI S Total 
Early treatment failure 254 59 30 18 361 
Late treatment failure 17 58 15 0 90 
Adequate clinical response 52 68 106 111 337 
Total 323 185 151 129 788 
Table 5. Multivariate regression analysis of risk of independent predictors 
of chloroquine treatment failure in study children with uncomplicated 
Plasrnodiurnfalciparutn malaria controlling for study site 
Variable Odds ratio 95 % CI P 
Age per month increase 0.97 0.96-0.98 <0.0001 
Temperature per 1 °C increase 1.28 1.062-1.545 <0.0098 
Parasitaemia per 10-fold increase 1.21 1.07-1.36 0.0019 
0 
0 
110- 
100- 
90- 
80- 
70 
/ 
- -  Adequate clinical response 
. . . . . . .  No adequate clinical response 
1L4 2~1 2~8 
Days since admission 
Figure. Mean haemoglobin concentration i  study children 
with uncomplicated Plasmodium falciparum malaria with and 
without adequate clinical response between days 0 and 28. 
Error bars indicate 95% CI. 
RI or RII resistance (Plowe et al., 2001). A recent study 
in Ghana also demonstrated this discordance (Ehrhardt 
et al., 2002). We encountered high rates of ETFs, 
which were usually associated with RII or RIII resis- 
tance. Only a small proportion of children had S or RI 
parasitological outcomes in the setting of early treat- 
ment failures. We also found that a small number of 
children with an ACR had RII or RIII resistance. 
Although our results are substantially different from 
those of Plowe et al. (2001), this may have been due to 
the higher levels of parasitological resistance and treat- 
ment failures present at our study sites. In Plowe's 
report, younger children were more likely to have 
discordance between ACR and evidence of parasitolo- 
gical resistance (Plowe e~ al., 2001). Since our study 
population only included children aged < 5 years, the 
greater degree of discordance between the parasitologi- 
cal resistance and therapeutic n vivo efficacy outcomes 
may have been largely due to the age range of our study 
population. 
Younger age, higher temperature, and greater density 
of parasitaemia were independent predictors of chloro- 
quine treatment failure in our study. Young age and 
high parasite density have been demonstrated in pre- 
vious studies to be predictors of antimalarial drug 
resistance (Hess et al., 1996; Dorsey et al., 2000; 
Ehrhardt et al., 2002). A presenting temperature 
> 38 °C was a predictor of treatment failure in Uganda 
(Dorsey et al., 2000). Our study also demonstrated that 
higher temperature was associated with an increased 
risk of chloroquine treatment failure. In addition, we 
demonstrated a progressive increase in the likelihood of 
treatment failure with rising temperature. A physiologi- 
cal explanation for the association between higher base- 
line temperature and risk of treatment failure is not 
apparent. 
Recent antimalarial treatment, which was predomi- 
nantly chloroquine, was not associated with an in- 
creased risk of treatment failure in our study. In 
contrast, Dorsey et al. (2000) found that patients who 
had taken chloroquine 3-14 d prior to study entry were 
more likely to be treatment failures when compared 
with patients who had not recently used chloroquine or 
who had been treated with chloroquine in the last 3 d 
(Dorsey et al., 2000). 
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Two l imitations of our study were the lack of urine 
testing for chloroquine and its metabolites and failure 
to define precisely when chloroquine was taken prior to 
presentat ion at the health centre. The  majority of the 
carers of the chi ldren in our study denied recent anti- 
malarial use. Previous studies have shown a high corre- 
lation between admitt ing to have taken an antimalarial 
and a positive urine test (Dorsey et al., 2000). However, 
the reliability of a pat ient 's  denial of recent antimalarial 
use is lower as many of these patients have detectable 
drug or metabol ites in their urine (Dorsey et al., 2000). 
The  lack of reliability of a negative report of recent 
antimalarial use complicates the interpretat ion of our 
data, which relied on carer recall. In addition, we did 
not ask the carers of the chi ldren in our study to define 
when antimalarials were taken. As a consequence, we 
cannot  conclusively state that recent chloroquine use is 
not a risk factor for t reatment  failure. Since recent 
chloroquine use has been associated with parasitologi- 
cal resistance in other studies (Henry et al., 1996; 
Bayoumi et al., 1997), there appears to be a reasonable 
probabil ity that this is also a predictor of t reatment  
failure. 
Another  potential  criticism of our study was our 
decision to not  take temperatures at days 7 and 14 in 
accordance with WHO guidelines (WHO,  1996). We 
relied instead on a report of recent fever. A negative 
report of fever has been shown to have a high negative 
predictive value whereas a positive response is of ques- 
t ionable reliability (Einterz & Bates, 1997, 1998; Ver- 
hoef  et al., 1998). Not  measuring temperature on days 
7 and 14 should only have had an impact on the 
outcome, LTF.  However, the independent  risk factors 
for t reatment  failure in our cohort of chi ldren (young 
age, higher temperature,  and higher parasite density) 
were most  strongly associated with ETF.  As a conse- 
quence, the use of recall data for recent fever is unlikely 
to have had a meaningful  impact on our study findings. 
Our entire study cohort was found to have worsening 
anaemia between baseline and day 7 with a gradual 
recovery of Hb over the following 3 weeks. Predictors 
of slower recovery of Hb in our study included younger 
age, higher presenting temperature,  and greater para- 
site density. In chi ldren with ETF ,  there was a delayed 
recovery of Hb relative to those children who had 
ACRs. A recent study in Tanzania  also found that 
chi ldren with ETF  had a significantly greater decrease 
in Hb level at 72 h (Ekvall et al., 1998). However, in 
contrast o our study, which demonstrated a rise in Hb  
level by days 14 and 28 to levels that were higher than 
at the t ime of hospital presentation, the Tanzan ian 
study found that all chi ldren who were treated with 
chloroquine did not recover to pre-treatment Hb  levels. 
Differences in the dietary intake of iron, phytates, and 
the prevalence of concomitant  parasitic infections (e.g. 
hookworm infections) are potential  explanations for the 
difference between our results and those of the Tanza-  
nian study. 
The  strengths of our study included a large sample 
size and the use of a consistent protocol with multiple 
quality control measures imultaneously in several dif- 
ferent countries with varying degrees of transmission, 
with resultant variable underlying partial immuni ty  of 
the population. The  independent  predictors of chloro- 
quine t reatment  failure derived from our results and 
those of others (Hess et al., 1996; Ekvall et al., 1998; 
Dorsey et al., 2000) can be used to risk-stratify chi ldren 
who might benefit  from immediate use of second-l ine 
antimalarials in countries with high levels of chloro- 
quine resistance. Because of the clear association be- 
tween treatment  failure and delayed recovery from 
anaemia, the association between repeated episodes of 
malaria and anaemia, known negative impact of anae- 
mia on physical activity and cognitive development in 
young children, and the need to reduce anaemia-asso- 
ciated blood transfusions in areas where hepatitis and 
H IV  are risks, countries that continue to use chloro- 
quine in the face of t reatment  failure rates > 25% must  
carefully re-evaluate their first-line t reatment  policies. 
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